| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.062 | 0.09 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.083 | 0.09 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | 0.066 | 0.09 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.082 | 0.09 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.1 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.081 | 0.1 |
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | -0.063 | 0.1 |
| mRNA | birinapant | CTRPv2 | pan-cancer | AAC | -0.063 | 0.1 |